enGene Therapeutics Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
enGene Therapeutics Inc. (ENGN) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $1.00 thousand for the 9-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-09-08
- enGene Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-01-31 was $1.00K, a 0.00% change year-over-year.
- enGene Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-01-31 was $1.00K, a 0.00% change year-over-year.
- enGene Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-01-31 was $1.00K, a 0.00% change year-over-year.
- enGene Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-01-31 was $1.00K.
- enGene Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $1.00K, a 0.00% change from fiscal 2024.
- enGene Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was $1.00K, a 0.00% change from fiscal 2023.
- enGene Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $1.00K.
- enGene Therapeutics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$805.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-07-31 | $1.00K 10-Q · filed 2026-09-08 | |||
| 2026-04-30 | $1.00K 10-Q · filed 2026-06-15 | |||
| 2026-01-31 | $1.00K 10-Q · filed 2026-03-09 | |||
| 2025-10-31 | $1.00K 10-K · filed 2025-12-22 | |||
| 2025-07-31 | $1.00K 10-Q · filed 2026-09-08 | |||
| 2025-04-30 | $1.00K 10-Q · filed 2026-06-15 | |||
| 2025-01-31 | $1.00K 10-Q · filed 2026-03-09 | |||
| 2024-10-31 | $1.00K 10-K · filed 2025-12-22 | |||
| 2024-07-31 | $1.00K 10-Q · filed 2025-09-11 | |||
| 2024-04-30 | $1.00K 10-Q · filed 2025-06-12 | |||
| 2024-01-31 | $1.00K 10-Q · filed 2025-03-10 | |||
| 2023-10-31 | $1.00K 10-K · filed 2024-12-19 | |||
| 2023-07-31 | $1.00K 10-Q · filed 2024-09-10 | |||
| 2023-04-30 | $1.00K 10-Q · filed 2024-06-14 | |||
| 2023-01-31 | $1.00K 10-Q · filed 2024-03-11 | |||
| 2022-10-31 | -$805.00K 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |